PharmAla Biotech Logo 800 x 422.png
PharmAla Data to be Published in ACS Chemical Neuroscience
February 20, 2024 08:55 ET | PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
Research Nester Logo.jpg
Biologics Contract Development & Manufacturing Organization Market revenue to hit USD 39 Billion by 2036, says Research Nester
February 08, 2024 05:30 ET | Research Nester
New York, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics contract development & manufacturing organization (CDMO) market size is projected to grow at a CAGR of over ~12% from 2024 to...
WeightWatchers New Logo 2023.png
Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform
February 07, 2024 09:05 ET | WW International Inc.
NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of...
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
January 31, 2024 04:00 ET | AKAMPION
New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstructionCompany aims to expand EU market authorization from custom-made to off-the-shelf products and...
Y-Prime_Logo_rgb_color.png
YPrime's Latest Research Reveals Significant Impact of eCOA Platform Delays on Clinical Trial Efficiency
January 30, 2024 08:00 ET | Y-Prime, LLC
YPrime eCOA research reveals stakeholders' concerns about timelines and data quality.
YPrime Brand Launch Image
YPrime Unveils a Transformative Brand Focused on Solving for Certainty in Clinical Trials
January 22, 2024 07:45 ET | Y-Prime, LLC
YPrime announces bold rebranding and re-commitment to provide cutting-edge technologies to streamline and accelerate clinical trials.
OBI Logo.jpg
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
January 03, 2024 05:00 ET | OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...
OBI Logo.jpg
OBI-992 获FDA核准展开一/二期临床试验
January 03, 2024 05:00 ET | OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2为标靶、自行研发的抗体药物复合体(ADC)新药OBI-992,已获美国食品药物管理局(FDA)核准一/二期临床试验申请,以评估其安全性及疗效。 ...
OBI Logo.jpg
OBI-992 獲FDA核准展開一/二期臨床試驗
January 03, 2024 05:00 ET | OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2為標靶、自行研發的抗體藥物複合體(ADC)新藥OBI-992,已獲美國食品藥物管理局(FDA)核准一/二期臨床試驗申請,以評估其安全性及療效。 ...
Sterling-800x800.png
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
January 02, 2024 08:00 ET | Sterling Infosystems, Inc
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening